Skip to Content
Søk Menu
Velkommen til lungekreft

Få de nyeste artiklene og MEDtalks om lungekreft

Siste nytt om lungekreft

Jens Benn’s Encounter with Heine Was Pivotal in His Choice of Lung Oncology

  • / Jens Benn Sørensen / Amanda Feldballe Bernholm
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungekreft Play the Video
Pasi Jänne

New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

/ Pasi Jänne
LungekreftNSCLCWCLC25 Play the Video
Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
LungekreftWCLC25 Play the Video

Lung Cancer Highlights

Norwegian and Nordic Lung Cancer Insights – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Lung Cancer Insights: What’s New in the Field

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft
Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
LungekreftNSCLC Play the Video

MEDtalks

Bjørn H Grønberg

Perioperativ behandling ved ikke-småcellet lungekreft

/ Bjørn Henning Grønberg
Lungekreft Play the Video
Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lungekreft Play the Video
Odd Terje Brustugun

Perspektiver på behandlingsvalg ved NSCLC uten drivermutasjoner

/ Odd Terje Brustugun
Lungekreft Play the Video
Bjørn H Grønberg

Kombinasjonsbehandling for EGFR-mutert lungekreft viser økt overlevelse

/ Bjørn Henning Grønberg
Lungekreft Play the Video
Miriam Grønberg

Treatment Timing Impacts Survival in Limited Stage Small Cell Lung Cancer

/ Miriam Grønberg
Lungekreft Play the Video
Nicolas Girard

Prophylactic Treatment Lowers Skin Toxicity in NSCLC Patients on Amivantamab + Lazertinib

/ Nicolas Girard
Lungekreft Play the Video
Load more

Artikler

New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

/ Jan Andreasen
LungekreftNSCLCWCLC25

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update

/ Jan Andreasen
LungekreftNSCLCWCLC25

First-Line NSCLC Without Driver Mutations: Practice, Gaps, and Costs

/ Ronny Öhman / Jan Andreasen
LungekreftNSCLC

Lazertinib + Amivantamab: A New Chemotherapy-Free Option for EGFR-Mutated Advanced NSCLC

/ Antonio Passaro / Jan Andreasen
Lungekreft

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungekreft

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungekreft

Back to top